Molecular Probes and Imaging Agents

Share:

EmailFacebookLinkedInXWhatsAppShare
This program supports development and biomedical application of molecular probes and imaging agents across all imaging modalities for the visualization, characterization and quantification of normal biological and pathophysiological processes and anatomy in living organisms at the molecular, cellular and organ levels.

Emphasis

The emphasis is on engineering of targeting and responsive molecular probes of high sensitivity and specificity for PET and SPECT (radiotracers), MR (T1, T2, CEST, hyperpolarized agents), EPR, CT, optical (fluorescent and bioluminescent probes), ultrasound (microbubbles) and photoacoustic imaging.  The imaging agents may be based on nano- and micro-particles, liposomes, dendrimers, proteins, small organic and inorganic molecules etc., and detectable by one or more imaging modalities.  Imaging agent development through methodologies such as chemical synthesis, biological mutagenesis, microfabrication, etc., may be pursued with an intent of leading to in vivo biomedical application.

Outcome

The goal of this program is to generate robust molecular probes, imaging agents and platforms for biomedical application across all disease areas to facilitate diagnostics and improve understanding of disease state, progression, and therapeutic response.

Additional emphasis

This program also supports the development of other imaging agents, for example:

  • multimodal molecular probes (PET/MRI, PET/fluorescent, etc.)
  • imaging reporter genes and reporter gene/imaging probe duos
  • molecular probes as part of theranostic systems or biosensors
  • imaging agents for cell labelling and in vivo tracking
  • molecular probes for image-guided interventions

Note

The following related scientific areas are supported by other NIBIB programs:

    Related News

    November 16, 2023

    Within one year of launching its incubator hubs, the National Institutes of Health Blueprint MedTech program has issued nine awards in its first competition cycle. The MedTech program seeks to

    September 21, 2023
    NIH will advance the development of home-based and point-of-care health technologies with awards to six technology research and development centers around the country. The centers comprise the Point of Care Technology Research Network (POCTRN) and will parlay the momentum of the original network established in 2007 by the NIBIB.
    July 24, 2023
    New recommendations from the NIH Rapid Acceleration of Diagnostics (RADx®) Tech Program provide a blueprint for the design and manufacture of more accessible diagnostic tests.
    June 6, 2023
    An artificial intelligence computer program that processes magnetic resonance imaging (MRI) can accurately identify changes in brain structure that result from repeated head injury, a new study in student athletes shows. These variations have not been captured by other traditional medical images such as computerized tomography (CT) scans. The new technology, researchers say, may help design new diagnostic tools to better understand subtle brain injuries that accumulate over time. Source: NYU Langone Health, NYU Grossman School of Medicine/Science Daily
    June 2, 2023
    An image of a thyroid tumor, produced by high-definition microvasculature imaging, shows the tumor's microvasculature in high detail.
    Researchers have shown that an automated cancer diagnostic method, which pairs cutting-edge ultrasound techniques with artificial intelligence, can accurately diagnose thyroid cancer, of which there are more than 40,000 new cases every year.